Literature DB >> 22548148

Statin of Preference to Treat Dyslipidaemia in Patients with Renal Dysfunction: Cues from (SATURN).

Khalid Al-Waili1, Tamima Al-Dughaishi, Khalid Al-Rasadi, Riad Bayoumi, Yajnavalka Banerjee.   

Abstract

Entities:  

Year:  2012        PMID： 22548148      PMCID： PMC3327576          DOI： 10.12816/0003122

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN： 2075-051X


× No keyword cloud information.
  8 in total

1.  Acute Coronary Syndrome, Diabetes and Hypertension: Oman must pay more attention to chronic non-communicable diseases.

Authors:  Lamk Al-Lamki
Journal:  Sultan Qaboos Univ Med J       Date:  2011-08-15

2.  Acute coronary syndrome in oman: results from the gulf registry of acute coronary events.

Authors:  Prashanth Panduranga; Kadhim Sulaiman; Ibrahim Al-Zakwani
Journal:  Sultan Qaboos Univ Med J       Date:  2011-08-15

3.  Benefits of lowering cholesterol in chronic kidney disease.

Authors:  Khalid Al-Rasadi; Yajnavalka Banerjee
Journal:  Lancet       Date:  2011-10-15       Impact factor: 79.321

4.  Effect of two intensive statin regimens on progression of coronary disease.

Authors:  Stephen J Nicholls; Christie M Ballantyne; Philip J Barter; M John Chapman; Raimund M Erbel; Peter Libby; Joel S Raichlen; Kiyoko Uno; Marilyn Borgman; Kathy Wolski; Steven E Nissen
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

6.  Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Authors:  James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 8.237

7.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Authors:  Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

8.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.